Targeted Genetics and University College London Participate in "Gene Therapy Horizons" Press Conference
29 5월 2008 - 9:00PM
Marketwired
BOSTON, MA and SEATTLE, WA and University College London today
announced participation in the third annual "Gene Therapy Horizons"
Lecture at the 11th Annual Meeting of the American Society of Gene
Therapy taking place this week at the Hynes Convention Center in
Boston.
Data will be presented from a Phase 1/2 clinical study in which
visual function was improved in young adults with Leber congenital
amaurosis (LCA), a rare and usually incurable form of blindness,
using gene therapy. The study titled, "Effect of Gene Therapy on
Visual Function in Leber Congenital Amaurosis," by Bainbridge,
et.al, first appeared in the May 22 issue of the New England
Journal of Medicine.
A complete list of this year's speakers and their biographies is
available at www.asgt.org/am08/.
LCA is an inherited retinal degenerative disease characterized
by severe impairment of vision from birth and total blindness by
the third decade of life. There is no treatment currently available
for LCA.
About Targeted Genetics Corporation
Targeted Genetics Corporation is a biotechnology company
committed to the development of innovative targeted molecular
therapies for the prevention and treatment of acquired and
inherited diseases with significant unmet medical need. Targeted
Genetics' proprietary Adeno-Associated Virus (AAV) technology
platform allows it to deliver genes that encode proteins to
increase gene function or RNAi to decrease or silence gene
function. Targeted Genetics' product development efforts target
inflammatory arthritis, AIDS prophylaxis, congestive heart failure
and Huntington's disease. To learn more about Targeted Genetics,
visit Targeted Genetics' website at www.targetedgenetics.com.
About UCL Institute of Ophthalmology and Moorfields Eye Hospital
NIHR Biomedical Research Center
The Center was established in April 2007, funded by the
Department of Health through the National Institute for Health
Research (NIHR). It is one of 12 NHS-university partnerships that
have been awarded Biomedical Research Center status, following an
international peer reviewed competition based on an outstanding
international reputation for medical research and expertise, and
experience of translating that research into the clinical
setting.
The results from this gene therapy trial are the first
significant outcome from the establishment of the center, and
strongly demonstrate its purpose -- to conduct translational
research designed to take advances in basic medical research from
the laboratory to the clinic, enabling patients to benefit more
quickly from new scientific breakthroughs.
Safe Harbor Statement under the Private Securities Litigation
Reform Act of 1995:
This release contains forward-looking statements regarding the
Company's liquidity and financial resources, its ability to fund
ongoing and future operations, its business strategy and product
development, including statements regarding the data collected in
the LCA study, the potential impact of the LCA study on our results
of operations and other statements about the Company's plans,
objectives, intentions and expectations. These statements involve
current expectations, forecasts of future events and other
statements that are not historical facts. Inaccurate assumptions
and known and unknown risks and uncertainties can affect the
accuracy of forward-looking statements. Factors that could affect
actual future events or results include, but are not limited to,
payments anticipated by the Company under product development
collaborations and contracts, the Company's actual expenses, the
Company's ability to raise capital when needed, the timing, nature
and results of the Company's clinical trials, potential development
of alternative technologies or more effective products by
competitors, the Company's ability to obtain and maintain
regulatory or institutional approvals, the Company's ability to
maintain its listing on the NASDAQ Capital Market and the Company's
ability to obtain, maintain and protect its intellectual property,
as well as other risk factors described in its filings with the
Securities and Exchange Commission (SEC), including in "Item 1A.
Risk Factors" in the Company's most recent annual report on Form
10-K for the year ended December 31, 2007 filed with the SEC. You
should not rely unduly on these forward-looking statements, which
apply only as of the date of this release. The Company undertakes
no duty to publicly announce or report revisions to these
statements as new information becomes available that may change the
Company's expectations.
Investor and Media Contact: Stacie D. Byars WeissComm Partners
206.660.2588 Email Contact Carolyn Wang WeissComm Partners
415.946.1065 Email Contact
Tecogen (NASDAQ:TGEN)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Tecogen (NASDAQ:TGEN)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024
